J&J reported Phase 1 results for its investigational once-daily oral drug JNJ-6143: 12 of 16 patients with advanced prostate cancer and measurable tumors achieved a complete or partial response, or 75%, and its shares moved higher. Leerink called the results a potential 'game-changer', and J&J could share future development plans at its Dec. 8 Enterprise Business Review. The article also notes Meta's plan to raise up to $95 billion in equity, SpaceX's $40 billion debt raise to finance Nvidia GPU purchases, and Anthropic's IPO filing. Microsoft shares edged higher after it offered voluntary buyouts to about 60,000 eligible employees, which the author sees as a function of optimizing its operating structure rather than a sign of slowing business. Microsoft is expected to generate roughly $8 billion of free cash flow next quarter, versus outflows of $9.9 billion at Amazon and $2.3 billion at Alphabet, according to FactSet.
Summary written by Upside AI from the original article. Read the source for full details.
Keywords
pharmaceuticalsJohnson & Johnsonhealthcareemployment
Open a keyword to see other news on the same topic.
Related tickers and likely impact
MSFT
• NeutralMicrosoft
Relevance: low
| Market | US stocks |
|---|---|
| Sector | Information Technology |
| Industry | Systems Software |
| Market cap | $3.9T |
| Close on 10/23/2026 | 524.51 |
| Change that session | +0.66% |
Impact is scored by AI from the headline and may be wrong. It is not investment advice.
Related news
- Johnson & Johnson Raised Its Dividend Every Year. Why Did It Trail the S&P 500?
Johnson & Johnson (NYSE:JNJ) has raised its dividend for 64 straight years, yet a plain S&P 500 index fund beat the stock over the past decade. A $1,000 investment 10 years ago with reinvested dividends would be worth $2,957.10 today, about $703 of it from dividends, versus $3,593.10 for the S&P 500 over the same period, excluding dividends. In the third quarter of 2026, about $7 billion in charges for a proposed talc settlement and two deals cut reported EPS to $0.09, while adjusted EPS was $2.59. The company expects $21 billion in free cash flow this year, but net debt is about $28 billion, and two recent deals are expected to cut 2027 adjusted EPS by $1.36; the article warns that if talc payments eat into free cash flow, dividend increases could shrink.
- 2 Dividend Stocks Crushing the Market in 2026 (and Which Ones Can Keep Going)
The article examines Johnson & Johnson (JNJ) and Amgen (AMGN), two dividend stocks that have outperformed the market in 2026. For J&J, revenue and earnings beat expectations and guidance was slightly raised, but its medtech unit faces weaker Impella demand and a Class 1 recall in the U.S.; the article still sees long-term prospects intact, citing new drug launches, the OTTAVA surgical system, a proposed $5.5 billion talc settlement and a 64-year dividend increase streak. Amgen's second-quarter revenue rose 10% to $10.1 billion despite FDA moves to remove Tavneos and falling denosumab sales after losing exclusivity. The article says growth drivers such as Tezspire, Tepezza and the MariTide obesity candidate could offset these headwinds.
- Why Johnson & Johnson Stock Dropped Today
Johnson & Johnson shares fell 6.8% by 12:30 p.m. ET Tuesday despite beating third-quarter earnings expectations and raising 2026 guidance. Adjusted earnings were $2.59 per share against an expected $2.53, and sales grew 5.9%. However, adjusted profit fell 7.5% and GAAP profit dropped to $0.09 per share, down 96%, due to a one-time charge for the proposed talc litigation resolution and deals involving Firefly Bio and Sail Biomedicines. Free cash flow rose more than 6% to $15.1 billion, and the company now expects 2026 sales to grow 7.4% to $101.2 billion with adjusted earnings of about $11.10 per share. The author argues the stock's valuation of more than 22x adjusted earnings and nearly 29x free cash flow is too high for roughly 7% growth, and rates it a 'sell.'
- Johnson & Johnson Q3 2026 Earnings Call Summary
- Johnson & Johnson Introduce Coronary IVL Catheter
Johnson & Johnson has launched the Shockwave C2 Aero Fly Coronary IVL catheter in the U.S., designed to treat calcified coronary artery lesions in half the time of previous coronary IVL devices. The catheter delivers pulses at double the speed and cuts pause time between cycles to five seconds, reducing treatment time from 230 seconds to 115 seconds and lowering patients’ ischemic time. Coronary artery disease is the leading cause of death globally, affecting an estimated 315 million people worldwide. The device will be showcased at TCT 2026 in San Diego, California, from October 31 to November 3, 2026.
- Jim Cramer says this healthcare stock is still a buy. Plus, what to do with BNY
In the recap of Wednesday's Morning Meeting, Jim Cramer said the S&P 500 and Nasdaq fell after warmer-than-expected September consumer inflation data, while semiconductor stocks kept weakening and money rotated into healthcare and consumer staples. Eli Lilly rose more than 3.5%, Cardinal Health and Johnson & Johnson gained over 1%, and Cramer said it is important to buy J&J right now despite its 5.7% drop on Tuesday after an imperfect earnings report. Bank stocks slumped after earnings, with Bank of America down 7.5%, Morgan Stanley down 3% and State Street down nearly 8%, putting pressure on Bank of New York ahead of its Thursday report. The CNBC Investing Club planned to exit its Honeywell position later Wednesday, and Cramer said he wants to hear from BNY before deciding whether to buy more to lower the cost basis.
Related markets
Latest news
- An AI label alone no longer wins lenders, JPMorgan says
JPMorgan says an AI label alone no longer secures financing, as lenders increasingly require companies to show they can fund investment, service debt and generate cash flow. Credit default swap (CDS) trading tied to major AI companies surged in September, with weekly trading averaging more than $9 billion according to Morgan Stanley, and the five-year CDS of one financing-dependent AI infrastructure company reached 1,100 basis points, implying a near or above 50% probability of default over five years. In a report published Oct. 23, J.P. Morgan Private Bank's Justin Biemann said the stress is concentrated in business models that need debt markets to stay open, though a deeper AI downturn could spill into other risk assets, including Bitcoin. He pointed to Lehman Brothers, whose CDS topped 1,400 basis points before its 2008 bankruptcy as an early warning, while large AI leaders with strong cash flow pay 50 to 120 basis points.
- Stock market today: Dow, S&P 500, Nasdaq drift lower as tech slides
Nasdaq-100 futures fell 0.3% on Tuesday morning, while Dow Jones futures were barely above flat and S&P 500 futures drifted lower after Monday's gains. AI stocks continued to draw renewed interest after Anthropic publicly filed its IPO prospectus on Monday, and South Korean chip stocks and the KOSPI index rose in Asia. Investors are also looking ahead to Alphabet and Microsoft's third-quarter results on Wednesday and to the Federal Reserve's two-day meeting starting Tuesday, where policymakers will weigh whether hotter-than-expected inflation warrants a rate hike. According to CME Group, markets price in just 10% odds of a hike.
- Song Da Cao Cuong offers 6 million shares
Song Da Cao Cuong (SCL) plans to offer 6 million common shares at 12,500 VND per share, expecting to raise 75 billion VND to increase charter capital, restructure funding and ensure financial balance. Subscription registration runs from Nov. 17, 2026 to Dec. 8, 2026, while the rights transfer period runs from Nov. 17 to Dec. 3, 2026. The company has charter capital of over 388.3 billion VND, is headquartered in Hai Phong and trades on UPCoM. Founded in 2007 with fly ash production, it has expanded into AAC blocks, panels, dry mortar, adhesives and artificial gypsum; 2025 net revenue was about 618.6 billion VND and after-tax profit about 64.3 billion VND. In 2024 revenue, bricks, panels, mortar and adhesives accounted for about 76.3%, while fly ash made up 19%.
- Receives 'huge' dividend from Vingroup subsidiary, HoSE-listed company reports its highest-ever profit
LIX Detergent (LIX) reported third-quarter 2026 net revenue of about 860 billion VND, up more than 10%, and a record profit of nearly 84 billion VND, up more than 84%. A key driver was financial income of nearly 64 billion VND, including 59.4 billion VND in dividends from Xalivico Co., Ltd., in which LIX holds 26% while Vingroup records the company as a subsidiary with 74%; no such dividend had been recognized in the first half of 2026. Selling expenses nearly doubled to more than 142 billion VND, and general and administrative expenses rose about 12%. For the nine months, net revenue reached about 2,728 billion VND, up more than 26%, and after-tax profit was nearly 164 billion VND, with LIX completing about 80% of its annual revenue target and 95% of its annual profit target.
- Binance files for Brazil crypto license ahead of Friday deadline
Binance submitted an application for a cryptocurrency service provider license to the Central Bank of Brazil on Oct. 23, through its local entity BBrasil, ahead of the Oct. 30 deadline for existing providers to keep operating under transitional arrangements. Effective Tuesday, Brazilian users face restrictions on crypto lending, margin trading and other services, and the exchange is delisting 22 crypto assets in the country. Binance hopes ongoing talks with the central bank will allow it to restore some discontinued products, though filing an application does not constitute regulatory approval.
- Unframe Removes Another Barrier Between AI Capabilities and Adoption
Unframe, an applied AI lab, announced its availability on the AWS, Google Cloud and Microsoft marketplaces. Enterprises can buy directly through their existing cloud accounts, applying committed cloud spend toward Unframe and following established approval workflows. Private offers let Unframe set tailored pricing, contract terms and usage parameters for individual customers. Global VP of Revenue Jacquelyn Goldberg said the move removes another barrier between identifying high-value AI use cases and putting them into production. The company says it delivers production-ready AI solutions in days, with measurable business impact in weeks.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.